Venom immunotherapy reduces large local reactions to insect stings - 15/08/11
Reprint requests: David B. K. Golden, MD, 7939 Honeygo Blvd, #219, Baltimore, MD 21236.Abstract |
Background |
Large local reactions to insect stings cause significant morbidity and impair quality of life. Venom immunotherapy is not recommended because of a low risk for future systemic reaction and unproven efficacy in preventing large local reactions.
Objective |
To determine the feasibility of performing a controlled trial to examine the efficacy of venom immunotherapy in reducing the size and duration of large local reactions.
Methods |
Sting challenge in 41 patients with previous large local reactions and positive venom skin tests caused large local reactions 16 cm or larger in 34 patients, and 29 consented to treatment. Venom immunotherapy was initiated in 19, and 10 were untreated controls. Sting challenge was repeated after 7 to 11 weeks (control patients then began venom immunotherapy), and annually for as long as 4 years.
Results |
After 7 to 11 weeks of treatment, the size and duration of large local reactions decreased 42% and 53%, respectively, in treated patients and 18% in controls (P < .01 for both). The response was similar after 1 year, and improved after 2 to 4 years to 60% and 70%, respectively.
Conclusions |
Venom immunotherapy significantly reduced the size and duration of the large local reactions, and the efficacy improved over a period of 2 to 4 years of treatment. Further studies are needed to establish the safety and efficacy of venom immunotherapy for large local reactions, the optimal duration of treatment, and the mechanism for the differences in degree and rate of clinical response compared with venom immunotherapy in systemic reactors.
Le texte complet de cet article est disponible en PDF.Key words : Insect sting, venom immunotherapy, large local reaction, Hymenoptera
Abbreviations used : LLR, VIT
Plan
| Supported by National Institutes of Health grant AI08270 and National Institutes of Health General Clinical Research Center grant 5MO1-RR02719. |
|
| Disclosure of potential conflict of interest: D. B. K. Golden is on the speakers’ bureau for ALK-Abelló, GlaxoSmithKline, AstraZeneca, and Novartis/Genentech; and has received research support from the National Institutes of Health. R. G. Hamilton is on the Scientific Advisory Board for Yulez Corp. The rest of the authors have declared that they have no conflict of interest. |
Vol 123 - N° 6
P. 1371-1375 - juin 2009 Retour au numéro
Article précédent
- Meta-analysis of filaggrin polymorphisms in eczema and asthma: Robust risk factors in atopic disease
- Elke Rodríguez, Hansjörg Baurecht, Esther Herberich, Stefan Wagenpfeil, Sara J. Brown, Heather J. Cordell, Alan D. Irvine, Stephan Weidinger
- The glucocorticoid receptor heterocomplex gene STIP1 is associated with improved lung function in asthmatic subjects treated with inhaled corticosteroids
- Gregory A. Hawkins, Ross Lazarus, Richard S. Smith, Kelan G. Tantisira, Deborah A. Meyers, Stephen P. Peters, Scott T. Weiss, Eugene R. Bleecker
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?